Keep up with the latest research in the fast-moving field of gene therapy

August 2017: tisagenlecleucel
For B-cell precursor acute lymphoblastic leukemia
(Approved May 2018 for relapsed or refractory large B-cell lymphoma)
October 2017: axicabtagene ciloleucel
For relapsed or refractory large B-cell lymphoma
(Approved April 2021 for relapsed or refractory follicular lymphoma)
December 2017: voretigene neparvovec-rzyl
For inherited retinal disease
May 2019: onasemnogene abeparvovec
For spinal muscular atrophy (type I)
July 2020: brexucabtagene autoleucel
For relapsed or refractory mantle cell lymphoma
(Approved October 2021 for relapsed or refractory B-cell precursor acute lymphoblastic leukemia)
February 2021: lisocabtagene maraleucel
For relapsed or refractory large B-cell lymphoma
March 2021: idecabtagene vicleucel
For relapsed or refractory multiple myeloma after four or more prior lines of therapy
August 2022: betibeglogene autotemcel
For β-thalassemia requiring regular red blood cell (RBC) transfusion
November 2022: etranacogene dezaparvovec-drlb
For hemophilia B (congenital Factor IX deficiency)
December 2022: nadofaragene firadenovec-vncg
For high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors
February 2023: ciltacabtagene autoleucel
For relapsed or refractory multiple myeloma
April 2023: omidubicel-onlv
For hematologic malignancies that are planned for umbilical cord blood transplantation following myeloablative conditioning
Discover the history of gene therapy
Check out our gene-therapy timeline to see how far the field has come.
Sign up to stay informed
Stay with Vertex as we continue to explore the evolving field of gene therapy.